In order to participate in the conference call, please call 1-877-407-8029 (
ABOUT
TG Therapeutics?is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit?www.tgtherapeutics.com, and follow us on Twitter?@TGTherapeutics?and?Linkedin.
Contact:
Investor
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489)
Option 4
Media
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489)
Option 6
(C) 2022 Electronic News Publishing, source